VolitionRx Limited rose 24.7% on Friday, November 13, 2026, on 56,181,141 shares, 6.6 times its average daily volume. Headlines around the move:
VolitionRx Limited (VNRX:NYSEMKT) closed at $0.230 on November 13, 2026, up 24.66% on the day. The stock trades 97.1% below its 52-week high of $7.80 and 43.8% above its 52-week low of $0.160. Over the past year, it lost 96.5%. VolitionRx Limited is part of the Health Care sector (Biotechnology: In Vitro & In Vivo Diagnostic Substances).
In 252 trading sessions since November 13, 2025, VNRX closed higher on 69 days (27%). Its best day was August 27, 2026 (+47.06%) and its worst was June 8, 2026 (-22.35%). The stock moved 10% or more in a single session 36 times. It opened at least 5% above the previous day's high 10 times.
VolitionRx Limited, a life sciences company, focuses on developing blood-based tests to diagnose a range of cancers. The company is involved in the development of epigenetic Nu.Q blood assays based on its Nucleosomics biomarker discovery platform. It develops blood assays in the Nu.Q-X family to detect nucleosomes containing specific nucleotides; and blood assays in the Nu.Q-V family to detect nucleosomes containing specific histone variants. The company also develops blood assays in the Nu.Q-M family to detect nucleosomes containing modified histones that are proteins for packaging and ordering DNA into nucleosomes; blood assays in the Nu.Q-A family to detect nucleosome-protein adducts; and a Nu.Q-T assay to detect cancer by detecting total blood nucleosome levels. In addition, it develops HyperGenomics tissue and blood-based tests to determine disease subtype following initial diagnosis and to decide appropriate therapy; NuQ tests for non-cancer conditions; and NuQ clinical diagnostic products. VolitionRX Limited is based in Singapore.
Find more stocks like VNRX with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.